Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026 |
| |
Authors: | Werb Daniel Wood Evan Kerr Thomas Hershfield Neil Palmer Robert W H Remis Robert S |
| |
Affiliation: | a British Columbia Centre for Excellence in HIV/AIDS, St. Paul''s Hospital, Vancouver, British Columbia, Canada b Division of AIDS, University of British Columbia, Vancouver, British Columbia, Canada c Dalla Lana School of Public Health, University of Toronto, 155 College Avenue, Room 512, Toronto, Ontario, Canada M5T 3M7 d Dalla Lana School of Public Health, University of Toronto, Canada |
| |
Abstract: | BackgroundCanadian injection drug users (IDUs) are at high risk of hepatitis C virus infection (HCV). However, little is known about the costs associated with their HCV-related medical treatment. We estimated the medical costs of treating HCV-infected IDUs from 2006 to 2026.MethodsWe employed a Markov model of entry through birth or immigration to exposure-related behaviours or experiences, HCV infection, progression to HCV sequelae and mortality for active and ex-IDUs in Canada. We estimated direct and indirect treatment costs using data from the Ontario Case Costing Initiative (OCCI).ResultApproximately 137,000 IDUs will suffer from HCV-related disease each year until 2026. Applying the OCCI cost data to the prevalence of HCV-related disease from 2006 to 2026 yielded an estimated cost of $3.96 billion CND to treat HCV-infected IDUs.ConclusionsSubstantial costs are associated with the treatment of HCV-related disease among Canadian IDUs. Given the lack of effective HCV prevention strategies in Canada, we must develop targeted evidence-based responses to prevent HCV transmission and ensure appropriate allocation of medical resources to meet the present and future treatment needs of HCV-infected IDUs. |
| |
Keywords: | Hepatitis C Injection drug use Treatment Costs Canada |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|